106 related articles for article (PubMed ID: 19591537)
1. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.
Steinhauser I; Langer K; Strebhardt K; Spänkuch B
J Drug Target; 2009 Sep; 17(8):627-37. PubMed ID: 19591537
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.
Spänkuch B; Steinhauser I; Wartlick H; Kurunci-Csacsko E; Strebhardt KI; Langer K
Neoplasia; 2008 Mar; 10(3):223-34. PubMed ID: 18320067
[TBL] [Abstract][Full Text] [Related]
3. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
[TBL] [Abstract][Full Text] [Related]
4. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
5. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
7. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
8. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
10. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
Steinhauser I; Spänkuch B; Strebhardt K; Langer K
Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
Jang YJ; Kim YS; Kim WH
Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
16. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
17. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.
Spänkuch B; Matthess Y; Knecht R; Zimmer B; Kaufmann M; Strebhardt K
J Natl Cancer Inst; 2004 Jun; 96(11):862-72. PubMed ID: 15173270
[TBL] [Abstract][Full Text] [Related]
18. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Dai QB; Zhu ZG
Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(1):40-4. PubMed ID: 16620646
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
20. Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells.
Nilsson EM; Brokken LJ; Narvi E; Kallio MJ; Härkönen PL
Mol Cell Endocrinol; 2012 Jul; 358(1):104-15. PubMed ID: 22465097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
